SynthesisJournal for immunotherapy of cancer2025

Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.

Pablo Jimenez-Labaig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.